(b) PROHIBITED ACTS.—Section 501 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 351) is amend-
ed by inserting after paragraph (j) the following: 
‘‘(k) If it is a drug approved under a covered applica-
tion (as defined in section 505–2(e)), the holder of which 
does not meet the requirements of paragraphs (1) and (2) 
of subsection (b) of such section.’’. 
(c) REQUIRED CONTENT OF AN ABBREVIATED NEW 
DRUG APPLICATION.—Section 505(j)(2)(A) of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
355(j)(2)(A)) is amended— 
(1) in clause (vii)(IV), by striking ‘‘and’’ at the 
end; 
(2) in clause (viii), by striking the period at the 
end and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(ix) if the drug is or contains an 
opioid for which a listing in schedule II or 
III (on a temporary or permanent basis) is 
in effect under section 202 of the Con-
trolled Substances Act, information to 
show that the applicant has proposed tech-
nologies, controls, or measures related to 
the packaging or disposal of the drug that 
are comparably effective to those required 
VerDate Sep 11 2014 
00:17 May 08, 2018
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H5687.IH
H5687
dlhill on DSK3GLQ082PROD with BILLS
for the applicable listed drug under section 
505–2, if applicable.’’. 
(d) GROUNDS FOR REFUSING TO APPROVE AN AB-
BREVIATED NEW DRUG APPLICATION.—Section 505(j)(4) 
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355(j)(4)), is amended— 
(1) in subparagraph (J), by striking ‘‘or’’ at the 
end; 
(2) in subparagraph (K), by striking the period 
at the end and inserting ‘‘; or’’; and 
(3) by adding at the end the following: 
‘‘(L) if the drug is a drug described in 
paragraph (2)(A)(ix) and the applicant has not 
proposed technologies, controls, or measures re-
lated to the packaging or disposal of such drug 
that the Secretary determines are comparably 
effective to those required for the applicable 
listed drug under section 505–2.’’. 
(e) RULES OF CONSTRUCTION.— 
(1) Any labeling describing technologies, con-
trols, or measures related to packaging, storage, or 
disposal intended to mitigate the risk of abuse or 
misuse of a drug product that is subject to an abbre-
viated new drug application, including labeling de-
scribing differences from the reference listed drug 
VerDate Sep 11 2014 
01:44 May 08, 2018
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H5687.IH
H5687
dlhill on DSK3GLQ082PROD with BILLS
resulting from the application of section 505–2 of 
the Federal Food, Drug, and Cosmetic Act, as 
added by subsection (a), shall not be construed— 
(A) as changes to labeling not permissible 
under clause (v) of section 505(j)(2)(A) of such 
Act (21 U.S.C. 355(j)(2)(A)), or a change in 
the conditions of use prescribed, recommended, 
or suggested in the labeling proposed for the 
new drug under clause (i) of such section; or 
(B) to prohibit approval of an abbreviated 
new drug application under subparagraph (B) 
or (G) of section 505(j)(4) of such Act (21 
U.S.C. 355(j)(4)). 
(2) For a covered application that is an applica-
tion submitted under subjection (j) of section 505 of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355), subparagraph (j)(2)(A) of such section 
505 shall not be construed to limit the type of data 
or information the Secretary of Health and Human 
Services may request or consider in connection with 
making any determination under section 505–2. 
(f) GAO REPORT.—Not later than 12 months after 
the date of enactment of this Act, the Comptroller General 
of the United States shall prepare and submit to the Con-
gress a report containing— 
VerDate Sep 11 2014 
01:44 May 08, 2018
Jkt 079200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H5687.IH
H5687
dlhill on DSK3GLQ082PROD with BILLS
(1) a description of available evidence, if any, 
on the effectiveness of site-of-use, in-home controlled 
substance disposal products and packaging tech-
nologies; 
(2) identification of ways in which such disposal 
products intended for use by patients, consumers, 
and other end users that are not registrants under 
the Controlled Substances Act, are made available to 
the public and barriers to the use of such disposal 
products; 
(3) identification of ways in which packaging 
technologies are made available to the public and 
barriers to the use of such technologies; 
(4) a description of Federal oversight, if any, of 
site-of-use, in-home controlled substance disposal 
products, including— 
(A) identification of the Federal agencies 
that oversee such products; 
(B) identification of the methods of dis-
posal of controlled substances recommended by 
these agencies for site-of-use, in-home disposal; 
and 
(C) a description of the effectiveness of 
such recommendations at preventing the diver-
sion of legally prescribed controlled substances; 
VerDate Sep 11 2014 
00:17 May 08, 2018
Jkt 079200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H5687.IH
H5687
dlhill on DSK3GLQ082PROD with BILLS
(5) a description of Federal oversight, if any, of 
controlled substance packaging technologies, includ-
ing— 
(A) identification of the Federal agencies 
that oversee such technologies; 
(B) identification of the technologies rec-
ommended by these agencies, including unit 
dose packaging, packaging that provides a set 
duration, or other packaging systems that may 
mitigate abuse or misuse; and 
(C) a description of the effectiveness of 
such recommendations at preventing the diver-
sion of legally prescribed controlled substances; 
and 
(6) recommendations on— 
(A) whether site-of-use, in-home controlled 
substance disposal products and packaging 
technologies require Federal oversight and, if 
so, which agencies should be responsible for 
such oversight and, as applicable, approval of 
such products or technologies; and 
(B) the potential role of the Federal Gov-
ernment in evaluating such products to ensure 
product efficacy. 
Æ 
VerDate Sep 11 2014 
00:17 May 08, 2018
Jkt 079200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6301
E:\BILLS\H5687.IH
H5687
dlhill on DSK3GLQ082PROD with BILLS